J. Freeman

发表

C. Krejsa, J. Freeman, Cecile M. Krejsa, 2009 .

Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 2: Exposure–response analyses for efficacy and safety variables

V. Kansra, J. Freeman, Xiaodong Wang, 2015, Journal of clinical pharmacology.

Peginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic

J. Freeman, Dennis M. Miller, Jeff Meyer, 2013, Journal of clinical and translational hepatology.

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

E. Heath, I. Puzanov, W. Miller, 2014, Journal of Immunotherapy for Cancer.

Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates

V. Kansra, J. Freeman, Xiaodong Wang, 2015, Journal of clinical pharmacology.

643 PEG-IFN-l: ANTIVIRAL ACTIVITY AND SAFETY PROFILE IN A 4-WEEK PHASE 1B STUDY IN RELAPSED GENOTYPE 1 HEPATITIS C INFECTION

M. Shiffman, J. Freeman, E. Lawitz, 2009 .

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

M. Shiffman, P. Marotta, J. Freeman, 2010, Hepatology.

Phase 1 b Study of Pegylated Interferon Lambda 1 With or Without Ribavirin in Patients with Chronic Genotype 1 Hepatitis C Virus Infection

A. D. Torre, M. Shiffman, P. Marotta, 2010 .

Pharmacokinetics and pharmacodynamics of pegylated interferon lambda-1 in cynomolgus monkeys.

S. Pederson, J. Freeman, K. Byrnes-Blake, 2012, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Interferon Lambda as a Potential New Therapeutic for Hepatitis C

J. Freeman, Dennis M. Miller, K. Klucher, 2009, Annals of the New York Academy of Sciences.

Pegylated interferons Lambda‐1a and alfa‐2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood mononuclear cells

Z. Kraft, J. Freeman, J. Friborg, 2014, Journal of viral hepatitis.

Chimeric antigen receptor T cells secreting anti-PD-L 1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model

S. Signoretti, W. Marasco, J. Sui, 2016 .

A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis

I. Trocóniz, J. Freeman, E. Asín-Prieto, 2019, European Journal of Clinical Microbiology & Infectious Diseases.

IL-21 induces in vivo immune activation of NK cells and CD8+ T cells in patients with metastatic melanoma and renal cell carcinoma

G. McArthur, I. Davis, A. Petri, 2008, Cancer Immunology, Immunotherapy.

Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL‐31 neutralizing antibody

S. Dillon, T. Bukowski, N. Hamacher, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Interferon-β1b in the treatment of secondary progressive MS

C. Pozzilli, C. Polman, R. Fitzpatrick, 2001, Neurology.

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.

C. Pozzilli, L. Kappos, C. Polman, 2001, Neurology.

Deep abdominal muscle activity following supratentorial stroke.

J. Marsden, G. Shum, J. Freeman, 2013, Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology.

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

M. Shiffman, P. Marotta, J. Freeman, 2010, Hepatology.

Development of Pharmacodynamic Assays to Assess Ex Vivo Masp-2 Inhibition and Their Use to Characterize the Pharmacodynamics of Narsoplimab (OMS721) in Humans and Monkeys

J. Freeman, J. Cummings, T. Dudler, 2020 .

788 PEG-INTERFERON LAMBDA (PEG-IL-29): TRANSLATION OF IN VITRO PRECLINICAL DATA TO CLINICAL RESULTS

J. Freeman, D. Hausman, M. Holdren, 2008 .